Monocytes and macrophages as nanomedicinal targets for improved diagnosis and treatment of disease

Expert Review of Molecular Diagnostics

Volumn 13, Issue 6, 2013, Pages 567-580

  Lameijer, Marnix A ^a   Tang, Jun ^b   Nahrendorf, Matthias ^c   Beelen, Robert H J ^a   Mulder, Willem J M ^b,d  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

anti inflammatory; diagnosis; macrophage; monocyte; nanomedicine; nanoparticles; treatment

Indexed keywords

CHITOSAN; DENDRIMER; DEXAMETHASONE; DIDANOSINE; DOXORUBICIN; FERUMOXYTOL; GELATIN; LIPOSOME; METHOTREXATE; NANOBODY; NANOPARTICLE; PHOSPHATIDYLETHANOLAMINE; PROSTAGLANDIN; QUANTUM DOT; RIFAMPICIN; TECHNETIUM 99M;

ATHEROSCLEROSIS; CANCER CELL; CARDIOVASCULAR DISEASE; CIRCULATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG DELIVERY SYSTEM; FLUORESCENCE IMAGING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENT CELL; MACROPHAGE; MONOCYTE; MONONUCLEAR CELL; NANOMEDICINE; NANOTECHNOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PNEUMONIA; REVIEW; RHEUMATOID ARTHRITIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUBERCULOSIS;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; DRUG DELIVERY SYSTEMS; HUMANS; MACROPHAGES; MONOCYTES; NANOMEDICINE; NANOPARTICLES; NEOPLASMS; PATHOLOGY, MOLECULAR;

EID: 84881117882     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.2013.819216     Document Type: Review

References (114)

1. Holmes B, Quie PG, Windhorst DB, Good RA. Fatal granulomatous disease of childhood. An inborn abnormality of phagocytic function. Lancet 1(7449), 1225-1228 (1966
2. Porcheray F, Viaud S, Rimaniol AC et al. Macrophage activation switching: An asset for the resolution of inflammation. Clin. Exp. Immunol. 142(3), 481-489 (2005
3. Swirski FK, Nahrendorf M, Etzrodt M et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 325(5940), 612-616 (2009
4. Yona S, Kim KW, Wolf Y et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity 38(1), 79-91 (2013
5. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: Cancer as a paradigm. Nat. Immunol. 11(10), 889-896 (2010
6. Swirski FK, Nahrendorf M. Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. Science 339(6116), 161-166 (2013
7. Cnop M, Welsh N, Jonas JC, Jörns A, Lenzen S, Eizirik DL. Mechanisms of pancreatic beta-cell death in Type 1 and Type 2 diabetes: Many differences, few similarities. Diabetes 54(Suppl. 2), S97-S107 (2005
8. Philips JA, Ernst JD. Tuberculosis pathogenesis and immunity. Annu. Rev. Pathol. 7, 353-384 (2012
9. Choi MR, Stanton-Maxey KJ, Stanley JK et al A cellular Trojan Horse for delivery of therapeutic nanoparticles into tumors. Nano Lett. 7(12), 3759-3765 (2007
10. Keliher EJ, Yoo J, Nahrendorf M et al. 89Zr-labeled dextran nanoparticles allow in vivo macrophage imaging. Bioconjug. Chem. 22(12), 2383-2389 (2011
11. Leuschner F, Dutta P, Gorbatov R et al. Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat. Biotechnol. 29(11), 1005-1010 (2011
12. Davignon JL, Hayder M, Baron M et al. Targeting monocytes/macrophages in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 52(4), 590-598 (2013
13. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 4(2), 145-160 (2005
14. Cormode DP, Skajaa T, Fayad ZA, Mulder WJ. Nanotechnology in medical imaging: Probe design and applications. Arterioscler. Thromb. Vasc. Biol. 29(7), 992-1000 (2009
15. Mout R, Moyano DF, Rana S, Rotello VM. Surface functionalization of nanoparticles for nanomedicine. Chem. Soc. Rev. 41(7), 2539-2544 (2012
16. Wang M, Thanou M. Targeting nanoparticles to cancer. Pharmacol. Res. 62(2), 90-99 (2010
17. Gautier EL, Jakubzick C, Randolph GJ. Regulation of the migration and survival of monocyte subsets by chemokine receptors and its relevance to atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 29(10), 1412-1418 (2009
18. Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 19(1), 71-82 (2003
19. Passlick B, Flieger D, Ziegler-Heitbrock HW. Identification and characterization of a novel monocyte subpopulation in human peripheral blood. Blood 74(7), 2527-2534 (1989
20. Robben PM, LaRegina M, Kuziel WA, Sibley LD. Recruitment of Gr-1+ monocytes is essential for control of acute toxoplasmosis. J. Exp. Med. 201(11), 1761-1769 (2005
21. Serbina NV, Pamer EG. Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. Nat. Immunol. 7(3), 311-317 (2006
22. Nahrendorf M, Swirski FK, Aikawa E et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J. Exp. Med. 204(12), 3037-3047 (2007
23. Yona S, Jung S. Monocytes: Subsets, origins, fates and functions. Curr. Opin. Hematol. 17(1), 53-59 (2010
24. Randolph GJ. Immunology. No need to coax monocytes. Science 332(6035), 1268-1269 (2011
25. Zigmond E, Varol C, Farache J et al. Ly6C hi monocytes in the inflamed colon give rise to proinflammatory effector cells and migratory antigen-presenting cells. Immunity 37(6), 1076-1090 (2012
26. Shi C, Pamer EG. Monocyte recruitment during infection and inflammation. Nat. Rev. Immunol. 11(11), 762-774 (2011
27. Saleh MN, Goldman SJ, LoBuglio AF et al. CD16+ monocytes in patients with cancer: Spontaneous elevation and pharmacologic induction by recombinant human macrophage colony-stimulating factor. Blood 85(10), 2910-2917 (1995
28. Schlitt A, Heine GH, Blankenberg S et al. CD14+CD16+ monocytes in coronary artery disease and their relationship to serum TNF-Alpha levels. Thromb. Haemost. 92(2), 419-424 (2004
29. Tacke F, Randolph GJ. Migratory fate and differentiation of blood monocyte subsets. Immunobiology 211(6-8), 609-618 (2006
30. Carlin LM, Stamatiades EG, Auffray C et al. Nr4a1-dependent Ly6C(low) monocytes monitor endothelial cells and orchestrate their disposal. Cell 153(2), 362-375 (2013
31. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol. 11(11), 723-737 (2011
32. Hume DA. Macrophages as APC and the dendritic cell myth. J. Immunol. 181(9), 5829-5835 (2008
33. Geissmann F, Gordon S, Hume DA, Mowat AM, Randolph GJ. Unravelling mononuclear phagocyte heterogeneity. Nat. Rev. Immunol. 10(6), 453-460 (2010
34. Henriksen K, Bollerslev J, Everts V, Karsdal MA. Osteoclast activity and subtypes as a function of physiology and pathology-implications for future treatments of osteoporosis. Endocr. Rev. 32(1), 31-63 (2011
35. Bilzer M, Roggel F, Gerbes AL. Role of Kupffer cells in host defense and liver disease. Liver Int. 26(10), 1175-1186 (2006
36. Martin TR, Frevert CW. Innate immunity in the lungs. Proc. Am. Thorac. Soc. 2(5), 403-411 (2005
37. Mebius RE, Kraal G. Structure and function of the spleen. Nat. Rev. Immunol. 5(8), 606-616 (2005
38. Zhang X, Mosser DM. Macrophage activation by endogenous danger signals. J. Pathol. 214(2), 161-178 (2008
39. Mahdavian Delavary B, van der Veer WM, van Egmond M, Niessen FB, Beelen RH. Macrophages in skin injury and repair. Immunobiology 216(7), 753-762 (2011
40. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: Tumor-Associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23(11), 549-555 (2002
41. Wynn TA, Barron L. Macrophages: Master regulators of inflammation and fibrosis. Semin. Liver Dis. 30(3), 245-257 (2010
42. Stout RD, Jiang C, Matta B, Tietzel I, Watkins SK, Suttles J. Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences. J. Immunol. 175(1), 342-349 (2005
43. Hagemann T, Lawrence T, McNeish I et al. 'Re-educating' tumor-Associated macrophages by targeting NF-kappaB. J. Exp. Med. 205(6), 1261-1268 (2008
44. Smith AM, Rahman FZ, Hayee B et al. Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn's disease. J. Exp. Med. 206(9), 1883-1897 (2009
45. Kinne RW, Stuhlmüller B, Burmester GR. Cells of the synovium in rheumatoid arthritis. Macrophages. Arthritis Res. Ther. 9(6), 224 (2007
46. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Invest. 117(1), 175-184 (2007
47. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 141(1), 39-51 (2010
48. Zhang BC, Gao J, Wang J, Rao ZG, Wang BC, Gao JF. Tumor-Associated macrophages infiltration is associated with peritu-moral lymphangiogenesis and poor prognosis in lung adenocarcinoma. Med. Oncol. 28(4), 1447-1452 (2011
49. Cortez-Retamozo V, Etzrodt M, Newton A et al. Origins of tumor-Associated macrophages and neutrophils. Proc. Natl Acad. Sci. USA 109(7), 2491-2496 (2012
50. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 454(7203), 436-444 (2008
51. Soria G, Ben-Baruch A. The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett. 267(2), 271-285 (2008
52. Bögels M, Braster R, Nijland PG et al. Carcinoma origin dictates differential skewing of monocyte function. Oncoimmunology 1(6), 798-809 (2012
53. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 473(7347), 317-325 (2011
54. Weber C, Noels H. Atherosclerosis: Current pathogenesis and therapeutic options. Nat. Med. 17(11), 1410-1422 (2011
55. Tacke F, Alvarez D, Kaplan TJ et al. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J. Clin. Invest. 117(1), 185-194 (2007
56. Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell 145(3), 341-355 (2011
57. Kadl A, Meher AK, Sharma PR et al. Identification of a novel macrophage phenotype that develops in response to atherogenic phospholipids via Nrf2. Circ. Res. 107(6), 737-746 (2010
58. Rekhter MD, Gordon D. Active proliferation of different cell types, including lymphocytes, in human atherosclerotic plaques. Am. J. Pathol. 147(3), 668-677 (1995
59. Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis (.). Annu. Rev. Immunol. 27, 165-197 (2009
60. Weber C, Zernecke A, Libby P. The multifaceted contributions of leukocyte subsets to atherosclerosis: Lessons from mouse models. Nat. Rev. Immunol. 8(10), 802-815 (2008
61. Moghimi SM, Hunter AC, Murray JC. Nanomedicine: Current status and future prospects. FASEB J. 19(3), 311-330 (2005
62. Albanese A, Tang PS, Chan WC. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu. Rev. Biomed. Eng. 14, 1-16 (2012
63. Chono S, Tauchi Y, Morimoto K. Influence of particle size on the distributions of liposomes to atherosclerotic lesions in mice. Drug Dev. Ind. Pharm. 32(1), 125-135 (2006
64. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat. Rev. Clin. Oncol. 7(11), 653-664 (2010
65. Singh R, Lillard JW Jr. Nanoparticle-based targeted drug delivery. Exp. Mol. Pathol. 86(3), 215-223 (2009
66. Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug Discov. 9(8), 615-627 (2010
67. Tang J, Lobatto ME, Read JC, Mieszawska AJ, Fayad ZA, Mulder WJ. Nanomedical Theranostics in Cardiovascular Disease. Curr. Cardiovasc. Imaging Rep. 5(1), 19-25 (2012
68. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: Therapeutic applications and developments. Clin. Pharmacol. Ther. 83(5), 761-769 (2008
69. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf. B Biointerfaces 75(1), 1-18 (2010
70. Baker JR Jr. Dendrimer-based nanoparticles for cancer therapy. Hematology Am. Soc. Hematol. Educ. Program 708-719 (2009
71. Cormode DP, Sanchez-Gaytan BL, Mieszawska AJ et al. Inorganic nanocrystals as contrast agents in MRI: Synthesis, coating and introduction of multifunctionality. NMR in Biomed. 10, 1002/nbm 2909 (2013
72. Torchilin VP. Micellar nanocarriers: Pharmaceutical perspectives. Pharm. Res. 24(1), 1-16 (2007
73. Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu. Rev. Med. 63, 185-198 (2012
74. Lobatto ME, Calcagno C, Metselaar JM et al. Imaging the efficacy of anti-inflammatory liposomes in a rabbit model of atherosclerosis by non-invasive imaging. Meth. Enzymol. 508, 211-228 (2012
75. Szekanecz Z, Koch AE. Macrophages and their products in rheumatoid arthritis. Curr. Opin. Rheumatol. 19(3), 289-295 (2007
76. Heinsbroek SE, Gordon S. The role of macrophages in inflammatory bowel diseases. Expert Rev. Mol. Med. 11, e14 (2009
77. Barnes PJ. Alveolar macrophages as orchestrators of COPD. COPD 1(1), 59-70 (2004
78. Kelly C, Jefferies C, Cryan SA. Targeted liposomal drug delivery to monocytes and macrophages. J. Drug Deliv. 2011, 727241 (2011
79. Epstein-Barash H, Gutman D, Markovsky E et al. Physicochemical parameters affecting liposomal bisphosphonates bioactivity for restenosis therapy: Internalization, cell inhibition, activation of cytokines and complement, and mechanism of cell death. J. Control. Release 146(2), 182-195 (2010
80. Fidler IJ, Raz A, Fogler WE, Kirsh R, Bugelski P, Poste G. Design of liposomes to improve delivery of macrophage-Augmenting agents to alveolar macrophages. Cancer Res. 40(12), 4460-4466 (1980
81. Ahsan F, Rivas IP, Khan MA, Torres Suarez AI. Targeting to macrophages: Role of physicochemical properties of particulate carriers-liposomes and microspheres-on the phagocytosis by macrophages. J. Control. Release 79(1-3), 29-40 (2002
82. Weissleder R, Kelly K, Sun EY, Shtatland T, Josephson L. Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat. Biotechnol. 23(11), 1418-1423 (2005
83. Lobatto ME, Fuster V, Fayad ZA, Mulder WJ. Perspectives and opportunities for nanomedicine in the management of atherosclerosis. Nat. Rev. Drug Discov. 10(11), 835-852 (2011
84. Daldrup-Link HE, Golovko D, Ruffell B et al. MRI of tumor-Associated macrophages with clinically applicable iron oxide nanoparticles. Clin. Cancer Res. 17(17), 5695-5704 (2011
85. Nahrendorf M, Keliher E, Marinelli B et al. Detection of macrophages in aortic aneurysms by nanoparticle positron emission tomography-computed tomography. Arterioscler. Thromb. Vasc. Biol. 31(4), 750-757 (2011
86. Cormode DP, Skajaa T, van Schooneveld MM et al Nanocrystal core high-density lipoproteins: A multimodality contrast agent platform. Nano Lett. 8(11), 3715-3723 (2008
87. Mieszawska AJ, Mulder WJ, Fayad ZA, Cormode DP. Multifunctional gold nanoparticles for diagnosis and therapy of disease. Mol. Pharm. 10(3), 831-847 (2013
88. Chen K, Conti PS. Target-specific delivery of peptide-based probes for PET imaging. Adv. Drug Deliv. Rev. 62(11), 1005-1022 (2010
89. Gorantla S, Dou H, Boska M et al. Quantitative magnetic resonance and SPECT imaging for macrophage tissue migration and nanoformulated drug delivery. J. Leukoc. Biol. 80(5), 1165-1174 (2006
90. Swirski FK, Pittet MJ, Kircher MF et al. Monocyte accumulation in mouse atherogenesis is progressive and proportional to extent of disease. Proc. Natl Acad. Sci. USA 103(27), 10340-10345 (2006
91. Gaglia JL, Guimaraes AR, Harisinghani M et al. Noninvasive imaging of pancreatic islet inflammation in type 1A diabetes patients. J. Clin. Invest. 121(1), 442-445 (2011
92. Leimgruber A, Berger C, Cortez-Retamozo V et al. Behavior of endogenous tumorassociated macrophages assessed in vivo using a functionalized nanoparticle. Neoplasia 11(5), 459-468 (2009
93. Shimizu K, Mitchell RN, Libby P. Inflammation and cellular immune responses in abdominal aortic aneurysms. Arterioscler. Thromb. Vasc. Biol. 26(5), 987-994 (2006
94. Lal S, Clare SE, Halas NJ. Nanoshellenabled photothermal cancer therapy: Impending clinical impact. Acc. Chem. Res. 41(12), 1842-1851 (2008
95. Lobatto ME, Fayad ZA, Silvera S et al. Multimodal clinical imaging to longitudinally assess a nanomedical anti-inflammatory treatment in experimental atherosclerosis. Mol. Pharm. 7(6), 2020-2029 (2010
96. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N. Engl. J. Med. 353(16), 1711-1723 (2005
97. Hrkach J, Von Hoff D, Mukkaram Ali M et al. Preclinical development and clinical translation of a PSMA-Targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci. Transl. Med. 4(128), 128ra39 (2012
98. Fu W, Wojtkiewicz G, Weissleder R, Benoist C, Mathis D. Early window of diabetes determinism in NOD mice, dependent on the complement receptor CRIg, identified by noninvasive imaging. Nat. Immunol. 13(4), 361-368 (2012
99. Weinstein JS, Varallyay CG, Dosa E et al. Superparamagnetic iron oxide nanoparticles: Diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review. J. Cereb. Blood Flow Metab. 30(1), 15-35 (2010
100. Yancy AD, Olzinski AR, Hu TC et al. Differential uptake of ferumoxtran-10 and ferumoxytol, ultrasmall superparamagnetic iron oxide contrast agents in rabbit: Critical determinants of atherosclerotic plaque labeling. J. Magn. Reson. Imaging 21(4), 432-442 (2005
101. Nahrendorf M, Zhang H, Hembrador S et al. Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation 117(3), 379-387 (2008
102. Uchida M, Kosuge H, Terashima M et al. Protein cage nanoparticles bearing the LyP-1 peptide for enhanced imaging of macrophage-rich vascular lesions. ACS Nano 5(4), 2493-2502 (2011
103. Put S, Schoonooghe S, Devoogdt N et al. SPECT Imaging of Joint Inflammation with Nanobodies Targeting the Macrophage Mannose Receptor in a Mouse Model for Rheumatoid Arthritis. J. Nucl. Med. (2013
104. Movahedi K, Schoonooghe S, Laoui D et al. Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-Associated macrophages. Cancer Res. 72(16), 4165-4177 (2012
105. Jackson H, Muhammad O, Daneshvar H et al. Quantum dots are phagocytized by macrophages and colocalize with experimental gliomas. Neurosurgery 60(3), 524-9; discussion 529 (2007
106. Vyas SP, Kannan ME, Jain S, Mishra V, Singh P. Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages. Int. J. Pharm. 269(1), 37-49 (2004
107. Nardin A, Lefebvre ML, Labroquère K, Faure O, Abastado JP. Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma. Curr. Cancer Drug Targets 6(2), 123-133 (2006
108. Homem de Bittencourt PI Jr, Lagranha DJ, Maslinkiewicz A et al. LipoCardium: Endothelium-directed cyclopentenone prostaglandin-based liposome formulation that completely reverses atherosclerotic lesions. Atherosclerosis 193(2), 245-258 (2006
109. Wijagkanalan W, Higuchi Y, Kawakami S, Teshima M, Sasaki H, Hashida M. Enhanced anti-inflammation of inhaled dexamethasone palmitate using mannosylated liposomes in an endotoxininduced lung inflammation model. Mol. Pharmacol. 74(5), 1183-1192 (2008
110. Thomas TP, Goonewardena SN, Majoros IJ et al. Folate-Targeted nanoparticles show efficacy in the treatment of inflammatory arthritis. Arthritis Rheum. 63(9), 2671-2680 (2011
111. Howard KA, Paludan SR, Behlke MA, Besenbacher F, Deleuran B, Kjems J. Chitosan/siRNA nanoparticle-mediated TNF-Alpha knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model. Mol. Ther. 17(1), 162-168 (2009
112. Chakravarthy KV, Davidson BA, Helinski JD et al. Doxorubicin-conjugated quantum dots to target alveolar macrophages and inflammation. Nanomedicine 7(1), 88-96 (2011
113. Kaur A, Jain S, Tiwary AK. Mannancoated gelatin nanoparticles for sustained and targeted delivery of didanosine: In vitro and in vivo evaluation. Acta Pharm. 58(1), 61-74 (2008
114. McCarthy JR, Korngold E, Weissleder R, Jaffer FA. A light-Activated theranostic nanoagent for targeted macrophage ablation in inflammatory atherosclerosis. Small 6(18), 2041-2049 (2010